top of page

OPZuid funding for collaboration project with SupraPolix

12 apr. 2024

Funding from Europe and the Province of North Brabant for Eindhoven based comapnies UPyTher and SupraPolix BV to bring a novel and improved therapy to patients with peritoneal cancer, with a total budget of EUR 2.8 million.

SupraPolix develops tailored injectable hydrogel materials for variousbi medical applications. Building on this hydrogel technology, UPyTher is pioneering an innovative treatment for patients with peritoneal cancer that enables administration of medicines into the peritoneal cavity.

Within the project INJECTOGELS SupraPolix and UPyTher work together to scale-up the production processes of these injectable gels and confirm their safe use as drug delivery platform for intraperitoneal therapy.

bottom of page